Curated News
By: NewsRamp Editorial Staff
August 31, 2026
TransCode's TTX-MC138 Shows Promise in Breast Cancer Bone Metastasis
TLDR
- TransCode's TTX-MC138 shows survival benefits in bone metastasis, signaling a potential edge in cancer treatment investment.
- TTX-MC138, using oligonucleotide nanotechnology, inhibits miR-10b, raising HOXD10, and safely accumulates in metastatic lesions.
- This breakthrough offers hope for advanced cancer patients by targeting metastasis with a well-tolerated therapy.
- A new study reveals that blocking microRNA-10b can shrink breast cancer bone tumors, a surprising twist in oncology.
Impact - Why it Matters
This news is important because it provides hope for patients with metastatic breast cancer, a condition that currently has limited treatment options and a poor prognosis. The preclinical data demonstrating that TTX-MC138 can effectively target and inhibit a key driver of metastasis (miR-10b) in bone lesions suggests a potential new therapeutic approach. If these results translate to human clinical trials, TTX-MC138 could become a first-in-class treatment that not only halts the spread of cancer to bones but also improves survival, addressing a critical unmet medical need. Furthermore, the therapy's ability to accumulate specifically in metastatic sites could minimize systemic toxicity, improving quality of life for patients. This development also validates the broader strategy of targeting microRNAs in oncology, which could lead to new treatments for other metastatic cancers.
Summary
In a significant advancement for cancer therapy, TransCode Therapeutics (NASDAQ: RNAZ) has announced promising preclinical results for its lead candidate, TTX-MC138, in treating breast cancer bone metastasis. The findings, published in the peer-reviewed journal Cancers, demonstrate that TTX-MC138, when administered systemically, accumulates in metastatic bone lesions, reduces the expression of the oncogenic microRNA-10b (miR-10b), and increases the expression of the tumor-suppressor HOXD10. This mechanism led to significant survival benefits in animal models compared to controls, with repeated dosing showing no systemic toxicity. This research reinforces TransCode's innovative approach of using proprietary oligonucleotide nanotechnology to inhibit miR-10b, a well-documented biomarker of metastasis, and suggests potential applications for other metastatic cancers.
TransCode Therapeutics is a clinical-stage company dedicated to developing RNA-based and immuno-oncology therapeutics for high-risk and advanced cancers. Beyond TTX-MC138, the company has a portfolio of other first-in-class candidates designed to harness the immune system to fight cancer. The company's newsroom can be accessed at https://ibn.fm/RNAZ for the latest updates. The full press release is available at https://ibn.fm/E6gbq.
The announcement was disseminated by BioMedWire (BMW), a specialized communications platform focusing on the biotechnology, biomedical, and life sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which provides a range of services including press release distribution, editorial syndication, and social media reach. BMW aims to deliver breaking news and actionable information to investors and the public, enhancing brand awareness for its clients.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode's TTX-MC138 Shows Promise in Breast Cancer Bone Metastasis
